Comment on CMS-2026-1256-0002
PhilipsOpposeBusiness
Summary: Philips, a health technology company, opposes the proposed repeal of alternative New Technology Add-on Payment (NTAP) pathways for certain FDA-designated breakthrough devices. They argue that removing these pathways could delay patient access to innovative technologies and increase financial risk for hospitals, requesting that CMS maintain the current pathways or provide a transition period instead.
Please see the attached comments to the Medicare Program: Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2027 Rates; Requirements for Quality Programs; and Other Policy Changes